74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Novavax Inc
Closed
SectorHealthcare
7.05 -5.24
Overview
Share price change
24h
Min
6.93
Max
7.45
Income | 40M -81M |
|---|---|
Sales | 3.8M 88M |
EPS | -0.52 |
Profit margin | -91.755 |
Employees | 952 |
EBITDA | 52M -53M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +90.76% upside |
Next Earnings | 9 May 2025 |
|---|
Market Cap | -299M 967M |
|---|---|
Previous open | 12.29 |
Previous close | 7.05 |
Technical Score
By Trading Central
Confidence
Very Strong Bullish Evidence
Novavax Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Novavax Inc Forecast
Price Target
By TipRanks
90.76% upside
12 Months Forecast
Average 14.25 USD 90.76%
High 19 USD
Low 9 USD
Based on 4 Wall Street analysts offering 12 month price targets forNovavax Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Novavax Inc
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
